Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CONy 2020 | Psychotherapy: how should we treat psychogenic seizures?

Daniel Goldenholz • 26 Oct 2020
CONy 2020
Epilepsy General

Daniel Goldenholz, MD, PhD, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, discusses the use of psychotherapy to treat patients with seizures of a psychogenic origin. Currently, there is no treatment for these patients as anti-seizure drugs prove ineffective. Therefore, despite minimal scientific evidence, psychotherapy could be an option. This interview took place during the Virtual World Congress on Controversies in Neurology (CONy) 2020.

Disclosures

Daniel Goldenholz has received grants from NIH and BIDMC. He is on the advisory board for Magic Leap and Epilepsy AI.

More from Daniel Goldenholz

A simulated randomized controlled trial for epilepsy
5:33
A simulated randomized controlled trial for epilepsy
Daniel Goldenholz • 11 Apr 2025
Developing an accurate seizure forecasting tool: advances and challenges
4:55
Developing an accurate seizure forecasting tool: advances and challenges
Daniel Goldenholz • 11 Apr 2025
The AI-enhanced neurologist: what does the future hold?
1:59
The AI-enhanced neurologist: what does the future hold?
Daniel Goldenholz • 11 Apr 2025
Impact of AI on the future of neurology
7:28
Impact of AI on the future of neurology
Daniel Goldenholz • 28 Apr 2023

Related Videos

Which emerging epilepsy therapies are likely to change clinical practice?
9:12
Which emerging epilepsy therapies are likely to change clinical practice?
William Alves Martins • 20 Oct 2026
Emerging gene therapies for Dravet syndrome and other DEEs
10:41
Emerging gene therapies for Dravet syndrome and other DEEs
William Alves Martins • 20 Oct 2026
Emerging precision therapies reshaping the antiseizure medication landscape in epilepsy
9:58
Emerging precision therapies reshaping the antiseizure medication landscape in epilepsy
William Alves Martins • 20 Oct 2026
Phase II/III POWER1: efficacy, safety and lessons learned for vormatrigine in epilepsy
8:05
Phase II/III POWER1: efficacy, safety and lessons learned for vormatrigine in epilepsy
William Alves Martins • 20 Oct 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals